Long-Term Effectiveness and Safety of Sirolimus Stent Implantation for Coronary In-Stent Restenosis

Liïstro, Francesco; Fineschi, Massimo; Grotti, Simone; Angioli, Paolo; Carrera, Arcangelo; Ducci, Kenneth; Gori, Tommaso; Falsini, Giovanni; Pierli, Carlo; Bolognese, Leonardo

doi:10.1016/j.jacc.2009.08.075

Cited by 19 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent registry study reported that SES used for treatment of bare metal in-stent restenosis exhibited sustained efficacy at 4 years with a target lesion revascularisation rate of only 11.1%. 83 …”

Section: Pci In Special Groupsmentioning

confidence: 99%

Almanac 2011: Stable Coronary Artery Disease. the National Society Journals Present Selected Research That Has Driven Recent Advances in Clinical Cardiology

Henderson¹

2011

Mater Sociomed

View full text Add to dashboard Cite

Section: Pci In Special Groupsmentioning

confidence: 99%

Almanac 2011: Stable Coronary Artery Disease. the National Society Journals Present Selected Research That Has Driven Recent Advances in Clinical Cardiology

Henderson¹

2011

Mater Sociomed

View full text Add to dashboard Cite

Surface modification of implanted cardiovascular metal stents: From antithrombosis and antirestenosis to endothelialization

Zhang

Liu

et al. 2013

J Biomedical Materials Res

View full text Add to dashboard Cite

Driven by the complications occurring with bare metal stents and drug-eluting stents, concerns have been raised over strategies for long-term safety, with respect to preventing or inhibiting stent thrombosis, restenosis, and in-stent restenosis in particularly. Surface modification is very important in constructing a buffer layer at the interface of the organic and inorganic materials and in ultimately obtaining long-term biocompatibility. In this review, we summarize the developments in surface modification of implanted cardiovascular metal stents. This review focuses on the modification of metal stents via coating drugs or biomolecules to enhance antithrombosis, antirestenosis, and/or endothelialization. In addition, we indicate the probable future work involving the modification of the metallic blood-contacting surfaces of stents and other cardiovascular devices that are under development.

show abstract

Treatment of in-stent restenosis with excimer laser coronary angioplasty: benefits over scoring balloon angioplasty alone

et al. 2016

View full text Add to dashboard Cite

Treatment of in-stent restenosis (ISR) is associated with a high incidence of recurrence. This study evaluated the clinical safety and 6-month efficacy of excimer laser coronary angioplasty (ELCA) before scoring balloon dilatation for the treatment of ISR. Twenty-three patients with ISR were included and treatment strategy of ISR was dependent on each operator. Twelve patients among those were treated with ELCA before scoring balloon dilatation (ELCA group) and 11 patients were treated with scoring balloon alone (non-ELCA group). Acute procedural results were evaluated by quantitative coronary angiography (QCA) and frequency domain optical coherence tomography (FD-OCT). Follow-up angiography was performed in all patients and the incidence of recurrent ISR and target lesion revascularization (TLR) was determined at 6 months after initial ISR treatment. Procedural success was achieved in all patients. Baseline clinical and angiographic characteristics were similar between groups. Maximum dilatation pressure of scoring balloon was significantly lower in the ELCA group than in the non-ELCA group (9.0 ± 3.1 vs. 14.9 ± 4.3 atm, p = 0.001). In follow-up angiography, the occurrence of TLR was similar between groups (16.7 vs. 45.5 %, p = 0.09), but the late luminal loss was significantly lower in the ELCA group (0.7 ± 0.6 vs. 1.3 ± 0.7 mm, p = 0.03). ELCA is a safe and feasible technique for the treatment of ISR and associated with a relatively low recurrent restenosis in comparison with scoring balloon dilatation alone.

show abstract

Long-Term Effectiveness and Safety of Sirolimus Stent Implantation for Coronary In-Stent Restenosis

Abstract: The clinical benefit of SES implantation for bare-metal stent ISR is maintained at 4 years with a low TLR rate and an overall incidence of stent thrombosis of 0.7% per year.

Cited by 19 publications

References 15 publications

Almanac 2011: Stable Coronary Artery Disease. the National Society Journals Present Selected Research That Has Driven Recent Advances in Clinical Cardiology

Almanac 2011: Stable Coronary Artery Disease. the National Society Journals Present Selected Research That Has Driven Recent Advances in Clinical Cardiology

Surface modification of implanted cardiovascular metal stents: From antithrombosis and antirestenosis to endothelialization

Treatment of in-stent restenosis with excimer laser coronary angioplasty: benefits over scoring balloon angioplasty alone

Contact Info

Product

Resources

About